Form 4: Solventum Director Carlos Alban Receives RSU Grant

Director Carlos Alban was granted 3,300 restricted stock units (RSUs) by Solventum Corp, vesting in May 2027.

Summary

• Director Carlos Alban received a grant of 3,300 Restricted Stock Units (RSUs) on May 15, 2026.
• Each RSU represents a contingent right to receive one share of Solventum Corp common stock upon settlement.
• The RSUs are scheduled to fully vest on May 15, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The RSUs will convert to common stock on May 15, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is a common practice among S&P 500 and mid-cap healthcare companies to align incentives.
• The one-year vesting schedule is consistent with standard director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; represents standard director equity compensation.

Next Steps

• Vesting of RSUs on May 15, 2027.

Key Dates

Keywords

Solventum, SOLV, Form 4, Insider Trading, Director Compensation, Restricted Stock Units